De Novo Biotherapeutics

Website

Developer of an mRNA-encoded anti-cancer treatment technology designed for relapsed or refractory lymphoma diseases. The company designs mRNA to produce bispecific antibodies that attract natural kill...

Healthcare
Seoul, South Korea
Founded 2021
23 employees
Website
Valuation
$0
Share Price
N/A
Total Raised
$8.4M
Last Round
N/A
Investors
+5 other investors
View all 5 investors
Valuation History
0 funding rounds on record
Cap Table
Ownership structure
Market Activity
Secondary transactions

Get the full picture

Create a free account to unlock De Novo Biotherapeutics's funding history, team members, investor details, and more.

15 free profiles/month · No credit card required